Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker CHE
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Spencer S. Lee executive vice president | CHE Chemed Corp | Sale | 1,000 | $547.61 | $547.6K Sale | Form 4 ↗ |
| Nov 3, 2026 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 2,000 | $537.90 | $1.1M Sale | Form 4 ↗ |
| Nov 2, 2026 | Spencer S. Lee executive vice president | CHE Chemed Corp | Sale | 920 | $537.17 | $494.2K Sale | Form 4 ↗ |
| Sep 28, 2026 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 2,000 | $513.45 | $1.0M Sale | Form 4 ↗ |
| Sep 18, 2026 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 2,000 | $501.40 | $1.0M Sale | Form 4 ↗ |
| Aug 21, 2026 | Spencer S. Lee executive vice president | CHE Chemed Corp | Sale | 1,000 | $541.04 | $541.0K Sale | Form 4 ↗ |
| Aug 21, 2026 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 2,000 | $541.16 | $1.1M Sale | Form 4 ↗ |
| Aug 3, 2026 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 2,000 | $539.51 | $1.1M Sale | Form 4 ↗ |
| Jul 31, 2026 | Patrick P. Grace Director | CHE Chemed Corp | Sale | 190 | $532.00 | $101.1K Sale | Form 4 ↗ |
| Jun 9, 2026 | Andrea R. Lindell Director | CHE Chemed Corp | Sale | 1,347 | $447.33 | $602.6K Sale | Form 4 ↗ |
| May 29, 2026 | George J. Walsh III Director | CHE Chemed Corp | Sale | 500 | $437.83 | $218.9K Sale | Form 4 ↗ |
| May 8, 2026 | Patrick P. Grace Director | CHE Chemed Corp | Sale | 60 | $425.78 | $25.5K Sale | Form 4 ↗ |
| May 1, 2026 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 2,000 | $421.13 | $842.3K Sale | Form 4 ↗ |
| Mar 27, 2026 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 1,500 | $369.37 | $554.1K Sale | Form 4 ↗ |
| Mar 12, 2026 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 2,000 | $403.18 | $806.4K Sale | Form 4 ↗ |
| Nov 24, 2025 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 2,000 | $437.55 | $875.1K Sale | Form 4 ↗ |
| Sep 26, 2025 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 3,000 | $461.28 | $1.4M Sale | Form 4 ↗ |
| Sep 9, 2025 | Patrick P. Grace Director | CHE Chemed Corp | Sale | 150 | $463.39 | $69.5K Sale | Form 4 ↗ |
| Aug 5, 2025 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 2,000 | $428.55 | $857.1K Sale | Form 4 ↗ |
| Aug 4, 2025 | George J. Walsh III Director | CHE Chemed Corp | Buy | 200 | $417.10 | $83.4K Buy | Form 4 ↗ |
| Aug 4, 2025 | Nicholas Michael Westfall Executive Vice President | CHE Chemed Corp | Sale | 10,012 | $421.91 | $4.2M Sale | Form 4 ↗ |
| May 16, 2025 | Spencer S. Lee executive vice president | CHE Chemed Corp | Sale | 1,500 | $577.99 | $867.0K Sale | Form 4 ↗ |
| May 7, 2025 | Spencer S. Lee executive vice president | CHE Chemed Corp | Sale | 1,500 | $577.86 | $866.8K Sale | Form 4 ↗ |
| May 5, 2025 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 1,500 | $576.45 | $864.7K Sale | Form 4 ↗ |
| Mar 31, 2025 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 1,000 | $615.33 | $615.3K Sale | Form 4 ↗ |
| Mar 6, 2025 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 2,000 | $593.67 | $1.2M Sale | Form 4 ↗ |
| Mar 3, 2025 | Spencer S. Lee executive vice president | CHE Chemed Corp | Sale | 1,326 | $592.25 | $785.3K Sale | Form 4 ↗ |
| Dec 30, 2024 | Brian C. Judkins VP and Chief Legal Officer | CHE Chemed Corp | Buy | 145 | $519.50 | $75.3K Buy | Form 4 ↗ |
| Nov 27, 2024 | Spencer S. Lee executive vice president | CHE Chemed Corp | Sale | 732 | $575.62 | $421.4K Sale | Form 4 ↗ |
| Nov 25, 2024 | Kevin J. McNamara president and CEO, Director | CHE Chemed Corp | Sale | 2,000 | $572.77 | $1.1M Sale | Form 4 ↗ |
| Nov 22, 2024 | Spencer S. Lee executive vice president | CHE Chemed Corp | Sale | 1,000 | $565.71 | $565.7K Sale | Form 4 ↗ |
| Mar 20, 2024 | Brian C. Judkins VP and Chief Legal Officer | CHE Chemed Corp | Sale | 11,158 | $645.00 | $7.2M Sale | Form 4/A ↗ |
32 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:54 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances